Histology-driven chemotherapy in soft tissue sarcomas

Current Treatment Options in Oncology

Volumn 12, Issue 1, 2011, Pages 32-45

  Scurr, Michelle ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANGIOSARCOMA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; KAPOSI SARCOMA; LEIOMYOSARCOMA; LIPOSARCOMA; MYXOSARCOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM STAGING; PROGNOSIS; SARCOMA;

EID: 79958011296     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0140-x     Document Type: Article

References (46)

1. Sleijfer S, Seynaeve C, Verweij J. Using single agent therapy in adult patients with advanced soft tissue sarcomas can still be considered standard. Oncologist 2005, 10:833-841. (Pubitemid 43152701)
2. Judson I, Radford J, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877 (Pubitemid 32323965)
3. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2185 patients treated with anthracycline-containing first-line regimens-a European Organization for the Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999, 17:150-157. (Pubitemid 29022388)
4. Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacological basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. The Oncologist 2007, 12:1351-1360 (Pubitemid 350232609)
5. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46:72-83. Whilst this is a review of retrospective data, it is a robust evaluation of both the prognostic variables and predictive factors for both response and survival outcomes for ifosfamide, which has not been achieved before this
6. Svancárová L, Blay JY, Judson IR, et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002, 38:556-559. (Pubitemid 34185396)
7. Okuno S, Ryan LM, Edmonson JH, et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 2003, 15:1696-1673.
8. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001, 19:3483-3489. (Pubitemid 32730085)
9. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9:491-498.
10. Ferraresi V, Ciccarese M, Cercato MC, et al. Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol 2008, 63:149-155
11. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults; a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 2000;18:2081-2086. (Pubitemid 30324361)
12. Hensley ML, Maki R Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002, 20:2824-2831. This is the sentinel study that demonstrated that the combination of gemcitabine and docetaxel had considerable activity in leiomyosarcomas and has had a profound impact on the management of patients with leiomyosarcomas as well as other subtypes shown subsequently to benefit (Pubitemid 34651511)
13. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755-2763. This study showed that the combination of gemcitabine and docetaxel had activity outside of leiomyosarcomas (Pubitemid 47123184)
14. Hensley ML, Blessing JA, Mannel R, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008, 109:329-334. (Pubitemid 351754961)
15. Hensley ML, Blessing JA, Degeest K, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008, 109:323-328.
16. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009, 112; 563-567.
17. Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft tissue sarcomas. Eur J Cancer 2002, 38:543-549. The importance of this study is that it has effectively opened a rational discussion about what is the important endpoints for efficacy in clinical trials of systemic treatment in soft tissue sarcomas (Pubitemid 34185394)
18. Carbonero R Supko J, Maki R, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicentre phase II and pharmacokinetic study. J Clin Oncol 2005, 23:5484-5492.
19. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation of the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 2005, 23:576-584. (Pubitemid 46224235)
20. Demetri GD, Chawla SP, von Mehren M, et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196 This study confirmed the efficacy of trabectedin in a histologically enriched population, and the benefit of the 24 hour infusion over the 3 hour infusion regimen
21. Coindre JM, Pedeutour F, Aurias A et al. Well-differentiated and dedifferentiated liposarcoma. Virchows Arch 2010, 456:167-179.
22. Orvieto E, Furlanetto A, Laurino L, et al: Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 2001, 18:267-273 (Pubitemid 33089754)
23. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy, Eur J Cancer 2005, 41:2853-2860. A good review of the differing chemoresponsiveness of the three subtypes of liposarcomas
24. Patel SR, Burgess M, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994;74:1265-1269.
25. Grosso F, Jones RL, Demetri GD, et al: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8:595-602. The specific responsiveness of myxoid liposarcomas to trabectedin is demonstrated with this retrospective analysis of patients treated within a compassionate usage programme (Pubitemid 46995623)
26. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcoma (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009, 20:1439-1444.
27. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86; 2034-2037.
28. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behaviour depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007, 18:2030-2036 (Pubitemid 350286245)
29. Fury MG, Antonescu CR Van Zee KJ, et al. A 14 year retrospective review of angiosarcoma: clinical characteristics, prognostic factors and treatment outcomes with surgery and chermotherapy. Cancer J 2005;11:241-247 (Pubitemid 44698813)
30. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2008, 44:2433-2436
31. Van Dalen EC, Michiels EM, Caron HN et al. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010,; (3) CD005006
32. Charrois GJ, Allen TM. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003, 306:1058-1067. (Pubitemid 37025314)
33. Krown SE, Northfelt DW, Osoba D et al. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004, 31 (suppl 13):36): 36-52. (Pubitemid 40023241)
34. Eiling S, Lischner S, Busch JO, et al. Complete remission of radiation-resistant angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br J Dermatol 2002, 147:150-153 (Pubitemid 34779452)
35. Wollina U, Füller J, Graefe T, et al. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J Cancer Res Clin Oncol 2001, 127:396-399. (Pubitemid 32453682)
36. Skubitz K, Haddad P. Paclitaxel and liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361-366. (Pubitemid 40993264)
37. Balcerzak SP, Benedetti J, Weiss GR, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A South West Oncology Group Study. Cancer 1995, 76:2248-2252
38. Casper ES, Waltzman RJ, Schwartz GK et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998, 16:442-446 (Pubitemid 28464852)
39. Penel N, Nguyen Bui B, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008, 26; 5269-5274. This study is important as it is a phase II prospective study in a very rare subtype that demonstrates that these studies are achievable with important results yielded
40. Van Hoesel Q, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994, 5; 539-542. (Pubitemid 24223507)
41. Spurrell E, Fisher C, Thomas JM, et al. Prognostic factors in advanced synovial sarcomas: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005, 16:437-444. (Pubitemid 40458321)
42. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin plus doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993, 11:1269-1275. (Pubitemid 23199129)
43. Le Cesne A, Antoine E, Spielmann M, et al. High dose ifosfamide: circumvention of resistance to standarddose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995, 13:1600-1608.
44. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 1994, 73:2506-2511. (Pubitemid 24155525)
45. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27:3126-32. This study demonstrates several important issues; activity of a novel agent with a tolerable toxicity profile, the utilisation of subtype stratification in order to better evaluate efficacy, and the use of progression free rate as the primary endpoint
46. Penel N, Van Glabbeke M, Marreaud S, et al. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2010; DOI: 10.1093/annonc/mdq608